Helix BioPharma Corp. shareholders have demonstrated strong support for the company's leadership and strategic initiatives through overwhelming approval of all agenda items at their Annual General and Special Meeting held on January 30, 2026. A total of 61,885,815 common shares were voted, representing 81.03% of the company's total issued and outstanding shares, indicating substantial shareholder engagement in the clinical-stage oncology company's governance.
The voting results show near-unanimous approval across all measures, with shareholders re-electing all four director nominees with approximately 99.99% support. Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube will continue serving on the board for the ensuing year. This continuity in leadership is significant for Helix as it advances its oncology pipeline, particularly its lead candidate L-DOS47, which has completed Phase Ib studies in non-small cell lung cancer.
Shareholders also approved the appointment of Clearhouse LLP as auditor with 99.99% support and authorized a potentially important corporate restructuring measure. The resolution regarding amendment to the company's articles to effect a share consolidation was approved with 99.99% of votes cast in favor. This authorization allows the board to consolidate issued and outstanding common shares at a ratio of up to five pre-consolidation shares for one post-consolidation share, with the board having sole discretion to determine the final ratio.
The importance of these voting results extends beyond routine corporate governance. The near-unanimous support suggests strong investor confidence in Helix's strategic direction as it develops novel therapies targeting hard-to-treat cancers. The share consolidation authorization could potentially improve the company's capital structure and market position as it advances its clinical programs. A detailed report on all meeting items will be filed on SEDAR+ at https://www.sedarplus.com.
For investors and industry observers, these results provide insight into shareholder sentiment toward Helix's progress in oncology research. The company, which trades on multiple exchanges including TSX under symbol "HBP," is developing a pipeline spearheaded by its bio-conjugate technology platform targeting CEACAM6-expressing solid tumors. More information about the company's research and development activities is available at https://www.helixbiopharma.com/.
The overwhelming shareholder approval comes as Helix continues to advance its clinical programs while navigating the inherent risks of drug development. The company's forward-looking statements acknowledge numerous uncertainties, including financing availability, clinical trial timelines, regulatory approvals, and partnership negotiations. These risks are detailed in the company's regulatory filings available through SEDAR+.
